Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Show more
Location: 1000 Skokie Boulevard, Wilmette, IL, 60091, United States | Website: https://www.monopartx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
351.7M
52 Wk Range
$3.90 - $58.94
Previous Close
$57.00
Open
$58.25
Volume
126,140
Day Range
$56.62 - $68.18
Enterprise Value
298.5M
Cash
53.25M
Avg Qtr Burn
-2.453M
Insider Ownership
34.25%
Institutional Own.
51.83%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALXN1840 (tiomolybdate choline) Details Wilson disease | NDA Submission | |
MNPR-101-Zr Details Cancer, Solid tumor/s | Phase 1 Data readout | |
MNPR-101-RIT Details Cancer | Phase 1 Update | |
MNPR-101-Lu Details Cancer | Phase 1a Data readout |